Moderna Surges After Saying Omicron Vaccine Ready Early 2022_老虎社区_美港股上老虎

Moderna Surges After Saying Omicron Vaccine Ready Early 2022

Bloomberg2021-11-30

(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required. The ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Melodykjh
·2021-11-30
Like
回复
1
举报
收起
- LLQ_:
  ok
  2021-11-30
  回复
  举报
Anh
·2021-11-30
Not sure if you've all taken the mRNA boosters but damn, you really do get knocked out 😅 looks like it's 2x jabs annually, for the foreseeable future.
回复
2
举报
收起
- ElsieDewey:
  I hope the virus will be eliminated as soon as possible. Twice a year is terrible.
  2021-12-02
  回复
  举报
- MurrayBulwer:
  That's too bad. I hate injections. Pfizer has developed drugs for export.
  2021-12-02
  回复
  举报
TTLZ
·2021-11-30
Ok
回复
5
举报
收起
- TTLZ:
  Ok
  2021-11-30
  回复
  举报
SSim
·2021-11-30
Like pls
回复
4
举报
收起
- 7cdb98ae:
  ok
  2021-11-30
  回复
  举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1199171840?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-30 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199171840","market":"us","top_or_hot":-1,"title":"Moderna Surges After Saying Omicron Vaccine Ready Early 2022","media":"Bloomberg","content":"<div>\n<p>(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.\nThe ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html\">网页链接</a>\n\n</div>\n","source":"lsy1612507957220","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges After Saying Omicron Vaccine Ready Early 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges After Saying Omicron Vaccine Ready Early 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 09:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.\nThe ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html","article_id":"1199171840","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199171840","pubTimestamp":1638236363,"columns":[],"sourceInfo":{"source_id":"lsy1612507957220","name":"finance.yahoo"},"weMediaInfo":null,"summary":"(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vac","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"translate_title":"莫德纳在表示奥米克隆疫苗于2022年初准备就绪后激增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"BNTX":0.9},"content_text":"(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.\nThe stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.\nModerna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.\n“Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”\nJefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.\nBioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":609330462,"gmtCreate":1638237285650,"gmtModify":1638237467752,"author":{"id":"3578543878235243","authorId":"3578543878235243","name":"Melodykjh","avatar":"https://static.tigerbbs.com/ecbb1673398e9c20ba51196d1fc7f00b","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3578543878235243","idStr":"3578543878235243"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609330462","repostId":1199171840,"repostType":4,"repost":{"id":"1199171840","kind":"news","pubTimestamp":1638236363,"share":"https://www.laohu8.com/m/news/1199171840?lang=zh_CN&edition=full","pubTime":"2021-11-30 09:39","market":"us","language":"en","title":"Moderna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199171840","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vac","content":"<p>(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.</p><p><blockquote>（彭博社）——Moderna Inc.公布了一年来最好的两天涨幅，此前该公司表示，如果需要，一种对抗冠状病毒奥密克戎株的新疫苗可能会在2022年初准备就绪。</blockquote></p><p> The stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&amp;P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.</p><p><blockquote>该股在周五全球风险资产抛售期间飙升21%后，上涨12%，至9月30日以来的最高水平，重新夺回了今年迄今为止标普500表现最佳的地位。首席医疗官保罗·伯顿(Paul Burton)周末表示，该公司在上周四感恩节动员了数百名员工，开始治疗奥密克戎病毒。</blockquote></p><p> Moderna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.</p><p><blockquote>Piper Sandler分析师Edward A.Tenthoff对该股给予跑赢大盘评级，他表示，Moderna的mRNA技术非常适合使疫苗适应新变种。</blockquote></p><p> “Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”</p><p><blockquote>Tenthoff在给客户的一份报告中写道：“Moderna在开发新型Covid-19疫苗方面处于更有利的地位，现在有能力每月生产数亿剂疫苗。”“新型冠状病毒不会消失，并将提供未来多年的收入。”</blockquote></p><p> Jefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee也对Moderna投资者表示乐观，他表示最新的利差应该会鼓励人们尽早获得提振，而该生物技术公司则专注于2022年的新版本。他说，Moderna“可以在60-90天内将新的候选药物推进临床试验”。</blockquote></p><p> BioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.</p><p><blockquote>BioNTech SE在美国交易中收盘上涨4.2%，此前该公司表示正在努力调整其Covid-19疫苗以应对奥密克戎变种，并预计如有必要将在100天内准备好新版本。该生物技术公司及其新冠疫苗合作伙伴辉瑞公司几个月前就制定了计划。辉瑞股价收盘下跌3%。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-11-30 09:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.</p><p><blockquote>（彭博社）——Moderna Inc.公布了一年来最好的两天涨幅，此前该公司表示，如果需要，一种对抗冠状病毒奥密克戎株的新疫苗可能会在2022年初准备就绪。</blockquote></p><p> The stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&amp;P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.</p><p><blockquote>该股在周五全球风险资产抛售期间飙升21%后，上涨12%，至9月30日以来的最高水平，重新夺回了今年迄今为止标普500表现最佳的地位。首席医疗官保罗·伯顿(Paul Burton)周末表示，该公司在上周四感恩节动员了数百名员工，开始治疗奥密克戎病毒。</blockquote></p><p> Moderna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.</p><p><blockquote>Piper Sandler分析师Edward A.Tenthoff对该股给予跑赢大盘评级，他表示，Moderna的mRNA技术非常适合使疫苗适应新变种。</blockquote></p><p> “Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”</p><p><blockquote>Tenthoff在给客户的一份报告中写道：“Moderna在开发新型Covid-19疫苗方面处于更有利的地位，现在有能力每月生产数亿剂疫苗。”“新型冠状病毒不会消失，并将提供未来多年的收入。”</blockquote></p><p> Jefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee也对Moderna投资者表示乐观，他表示最新的利差应该会鼓励人们尽早获得提振，而该生物技术公司则专注于2022年的新版本。他说，Moderna“可以在60-90天内将新的候选药物推进临床试验”。</blockquote></p><p> BioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.</p><p><blockquote>BioNTech SE在美国交易中收盘上涨4.2%，此前该公司表示正在努力调整其Covid-19疫苗以应对奥密克戎变种，并预计如有必要将在100天内准备好新版本。该生物技术公司及其新冠疫苗合作伙伴辉瑞公司几个月前就制定了计划。辉瑞股价收盘下跌3%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199171840","content_text":"(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.\nThe stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.\nModerna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.\n“Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”\nJefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.\nBioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.","news_type":1,"symbols_score_info":{"MRNA":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6779211,"gmtCreate":1638238827294,"gmtModify":1638238827382,"authorId":4100083893976530,"author":{"id":4100083893976530,"idStr":"4100083893976530","authorId":4100083893976530,"name":"LLQ_","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609330462,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"CN"},{"id":609399469,"gmtCreate":1638236602813,"gmtModify":1638237464796,"author":{"id":"3555249757581559","authorId":"3555249757581559","name":"Anh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3555249757581559","idStr":"3555249757581559"},"htmlText":"Not sure if you've all taken the mRNA boosters but damn, you really do get knocked out 😅 looks like it's 2x jabs annually, for the foreseeable future.&nbsp;","listText":"Not sure if you've all taken the mRNA boosters but damn, you really do get knocked out 😅 looks like it's 2x jabs annually, for the foreseeable future.&nbsp;","text":"Not sure if you've all taken the mRNA boosters but damn, you really do get knocked out 😅 looks like it's 2x jabs annually, for the foreseeable future.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/609399469","repostId":1199171840,"repostType":4,"repost":{"id":"1199171840","kind":"news","pubTimestamp":1638236363,"share":"https://www.laohu8.com/m/news/1199171840?lang=zh_CN&edition=full","pubTime":"2021-11-30 09:39","market":"us","language":"en","title":"Moderna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199171840","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vac","content":"<p>(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.</p><p><blockquote>（彭博社）——Moderna Inc.公布了一年来最好的两天涨幅，此前该公司表示，如果需要，一种对抗冠状病毒奥密克戎株的新疫苗可能会在2022年初准备就绪。</blockquote></p><p> The stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&amp;P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.</p><p><blockquote>该股在周五全球风险资产抛售期间飙升21%后，上涨12%，至9月30日以来的最高水平，重新夺回了今年迄今为止标普500表现最佳的地位。首席医疗官保罗·伯顿(Paul Burton)周末表示，该公司在上周四感恩节动员了数百名员工，开始治疗奥密克戎病毒。</blockquote></p><p> Moderna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.</p><p><blockquote>Piper Sandler分析师Edward A.Tenthoff对该股给予跑赢大盘评级，他表示，Moderna的mRNA技术非常适合使疫苗适应新变种。</blockquote></p><p> “Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”</p><p><blockquote>Tenthoff在给客户的一份报告中写道：“Moderna在开发新型Covid-19疫苗方面处于更有利的地位，现在有能力每月生产数亿剂疫苗。”“新型冠状病毒不会消失，并将提供未来多年的收入。”</blockquote></p><p> Jefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee也对Moderna投资者表示乐观，他表示最新的利差应该会鼓励人们尽早获得提振，而该生物技术公司则专注于2022年的新版本。他说，Moderna“可以在60-90天内将新的候选药物推进临床试验”。</blockquote></p><p> BioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.</p><p><blockquote>BioNTech SE在美国交易中收盘上涨4.2%，此前该公司表示正在努力调整其Covid-19疫苗以应对奥密克戎变种，并预计如有必要将在100天内准备好新版本。该生物技术公司及其新冠疫苗合作伙伴辉瑞公司几个月前就制定了计划。辉瑞股价收盘下跌3%。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-11-30 09:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.</p><p><blockquote>（彭博社）——Moderna Inc.公布了一年来最好的两天涨幅，此前该公司表示，如果需要，一种对抗冠状病毒奥密克戎株的新疫苗可能会在2022年初准备就绪。</blockquote></p><p> The stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&amp;P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.</p><p><blockquote>该股在周五全球风险资产抛售期间飙升21%后，上涨12%，至9月30日以来的最高水平，重新夺回了今年迄今为止标普500表现最佳的地位。首席医疗官保罗·伯顿(Paul Burton)周末表示，该公司在上周四感恩节动员了数百名员工，开始治疗奥密克戎病毒。</blockquote></p><p> Moderna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.</p><p><blockquote>Piper Sandler分析师Edward A.Tenthoff对该股给予跑赢大盘评级，他表示，Moderna的mRNA技术非常适合使疫苗适应新变种。</blockquote></p><p> “Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”</p><p><blockquote>Tenthoff在给客户的一份报告中写道：“Moderna在开发新型Covid-19疫苗方面处于更有利的地位，现在有能力每月生产数亿剂疫苗。”“新型冠状病毒不会消失，并将提供未来多年的收入。”</blockquote></p><p> Jefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee也对Moderna投资者表示乐观，他表示最新的利差应该会鼓励人们尽早获得提振，而该生物技术公司则专注于2022年的新版本。他说，Moderna“可以在60-90天内将新的候选药物推进临床试验”。</blockquote></p><p> BioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.</p><p><blockquote>BioNTech SE在美国交易中收盘上涨4.2%，此前该公司表示正在努力调整其Covid-19疫苗以应对奥密克戎变种，并预计如有必要将在100天内准备好新版本。该生物技术公司及其新冠疫苗合作伙伴辉瑞公司几个月前就制定了计划。辉瑞股价收盘下跌3%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199171840","content_text":"(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.\nThe stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.\nModerna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.\n“Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”\nJefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.\nBioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.","news_type":1,"symbols_score_info":{"MRNA":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6814104,"gmtCreate":1638443288014,"gmtModify":1638443288014,"authorId":9000000000000603,"author":{"id":9000000000000603,"idStr":"9000000000000603","authorId":9000000000000603,"name":"ElsieDewey","avatar":"https://static.tigerbbs.com/f5db46fc82ad451b6aa0d938d2221d70","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609399469,"type":1,"supId":0,"prevId":0,"content":"I hope the virus will be eliminated as soon as possible. Twice a year is terrible.","text":"I hope the virus will be eliminated as soon as possible. Twice a year is terrible.","html":"I hope the virus will be eliminated as soon as possible. Twice a year is terrible."},{"id":6814083,"gmtCreate":1638443069428,"gmtModify":1638443069428,"authorId":9000000000000463,"author":{"id":9000000000000463,"idStr":"9000000000000463","authorId":9000000000000463,"name":"MurrayBulwer","avatar":"https://static.tigerbbs.com/86339b64cf42eeac7905c45fdbbed7fb","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609399469,"type":1,"supId":0,"prevId":0,"content":"That's too bad. I hate injections. Pfizer has developed drugs for export.","text":"That's too bad. I hate injections. Pfizer has developed drugs for export.","html":"That's too bad. I hate injections. Pfizer has developed drugs for export."}],"langContent":"CN"},{"id":609390213,"gmtCreate":1638236506232,"gmtModify":1638237153637,"author":{"id":"3581826176705129","authorId":"3581826176705129","name":"TTLZ","avatar":"https://static.tigerbbs.com/3285bfaae2742e85571cc7d44bad2420","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3581826176705129","idStr":"3581826176705129"},"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609390213","repostId":1199171840,"repostType":4,"repost":{"id":"1199171840","kind":"news","pubTimestamp":1638236363,"share":"https://www.laohu8.com/m/news/1199171840?lang=zh_CN&edition=full","pubTime":"2021-11-30 09:39","market":"us","language":"en","title":"Moderna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199171840","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vac","content":"<p>(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.</p><p><blockquote>（彭博社）——Moderna Inc.公布了一年来最好的两天涨幅，此前该公司表示，如果需要，一种对抗冠状病毒奥密克戎株的新疫苗可能会在2022年初准备就绪。</blockquote></p><p> The stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&amp;P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.</p><p><blockquote>该股在周五全球风险资产抛售期间飙升21%后，上涨12%，至9月30日以来的最高水平，重新夺回了今年迄今为止标普500表现最佳的地位。首席医疗官保罗·伯顿(Paul Burton)周末表示，该公司在上周四感恩节动员了数百名员工，开始治疗奥密克戎病毒。</blockquote></p><p> Moderna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.</p><p><blockquote>Piper Sandler分析师Edward A.Tenthoff对该股给予跑赢大盘评级，他表示，Moderna的mRNA技术非常适合使疫苗适应新变种。</blockquote></p><p> “Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”</p><p><blockquote>Tenthoff在给客户的一份报告中写道：“Moderna在开发新型Covid-19疫苗方面处于更有利的地位，现在有能力每月生产数亿剂疫苗。”“新型冠状病毒不会消失，并将提供未来多年的收入。”</blockquote></p><p> Jefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee也对Moderna投资者表示乐观，他表示最新的利差应该会鼓励人们尽早获得提振，而该生物技术公司则专注于2022年的新版本。他说，Moderna“可以在60-90天内将新的候选药物推进临床试验”。</blockquote></p><p> BioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.</p><p><blockquote>BioNTech SE在美国交易中收盘上涨4.2%，此前该公司表示正在努力调整其Covid-19疫苗以应对奥密克戎变种，并预计如有必要将在100天内准备好新版本。该生物技术公司及其新冠疫苗合作伙伴辉瑞公司几个月前就制定了计划。辉瑞股价收盘下跌3%。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-11-30 09:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.</p><p><blockquote>（彭博社）——Moderna Inc.公布了一年来最好的两天涨幅，此前该公司表示，如果需要，一种对抗冠状病毒奥密克戎株的新疫苗可能会在2022年初准备就绪。</blockquote></p><p> The stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&amp;P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.</p><p><blockquote>该股在周五全球风险资产抛售期间飙升21%后，上涨12%，至9月30日以来的最高水平，重新夺回了今年迄今为止标普500表现最佳的地位。首席医疗官保罗·伯顿(Paul Burton)周末表示，该公司在上周四感恩节动员了数百名员工，开始治疗奥密克戎病毒。</blockquote></p><p> Moderna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.</p><p><blockquote>Piper Sandler分析师Edward A.Tenthoff对该股给予跑赢大盘评级，他表示，Moderna的mRNA技术非常适合使疫苗适应新变种。</blockquote></p><p> “Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”</p><p><blockquote>Tenthoff在给客户的一份报告中写道：“Moderna在开发新型Covid-19疫苗方面处于更有利的地位，现在有能力每月生产数亿剂疫苗。”“新型冠状病毒不会消失，并将提供未来多年的收入。”</blockquote></p><p> Jefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee也对Moderna投资者表示乐观，他表示最新的利差应该会鼓励人们尽早获得提振，而该生物技术公司则专注于2022年的新版本。他说，Moderna“可以在60-90天内将新的候选药物推进临床试验”。</blockquote></p><p> BioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.</p><p><blockquote>BioNTech SE在美国交易中收盘上涨4.2%，此前该公司表示正在努力调整其Covid-19疫苗以应对奥密克戎变种，并预计如有必要将在100天内准备好新版本。该生物技术公司及其新冠疫苗合作伙伴辉瑞公司几个月前就制定了计划。辉瑞股价收盘下跌3%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199171840","content_text":"(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.\nThe stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.\nModerna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.\n“Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”\nJefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.\nBioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.","news_type":1,"symbols_score_info":{"MRNA":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6778656,"gmtCreate":1638236511966,"gmtModify":1638236512052,"authorId":3581826176705129,"author":{"id":3581826176705129,"idStr":"3581826176705129","authorId":3581826176705129,"name":"TTLZ","avatar":"https://static.tigerbbs.com/3285bfaae2742e85571cc7d44bad2420","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609390213,"type":1,"supId":0,"prevId":0,"content":"Ok ","text":"Ok ","html":"Ok "}],"langContent":"CN"},{"id":609390026,"gmtCreate":1638236464216,"gmtModify":1638237131018,"author":{"id":"3573512309350380","authorId":"3573512309350380","name":"SSim","avatar":"https://static.tigerbbs.com/bc347d90f5e5fb868ce6d6c9cf5f4763","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3573512309350380","idStr":"3573512309350380"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609390026","repostId":1199171840,"repostType":4,"repost":{"id":"1199171840","kind":"news","pubTimestamp":1638236363,"share":"https://www.laohu8.com/m/news/1199171840?lang=zh_CN&edition=full","pubTime":"2021-11-30 09:39","market":"us","language":"en","title":"Moderna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199171840","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vac","content":"<p>(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.</p><p><blockquote>（彭博社）——Moderna Inc.公布了一年来最好的两天涨幅，此前该公司表示，如果需要，一种对抗冠状病毒奥密克戎株的新疫苗可能会在2022年初准备就绪。</blockquote></p><p> The stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&amp;P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.</p><p><blockquote>该股在周五全球风险资产抛售期间飙升21%后，上涨12%，至9月30日以来的最高水平，重新夺回了今年迄今为止标普500表现最佳的地位。首席医疗官保罗·伯顿(Paul Burton)周末表示，该公司在上周四感恩节动员了数百名员工，开始治疗奥密克戎病毒。</blockquote></p><p> Moderna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.</p><p><blockquote>Piper Sandler分析师Edward A.Tenthoff对该股给予跑赢大盘评级，他表示，Moderna的mRNA技术非常适合使疫苗适应新变种。</blockquote></p><p> “Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”</p><p><blockquote>Tenthoff在给客户的一份报告中写道：“Moderna在开发新型Covid-19疫苗方面处于更有利的地位，现在有能力每月生产数亿剂疫苗。”“新型冠状病毒不会消失，并将提供未来多年的收入。”</blockquote></p><p> Jefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee也对Moderna投资者表示乐观，他表示最新的利差应该会鼓励人们尽早获得提振，而该生物技术公司则专注于2022年的新版本。他说，Moderna“可以在60-90天内将新的候选药物推进临床试验”。</blockquote></p><p> BioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.</p><p><blockquote>BioNTech SE在美国交易中收盘上涨4.2%，此前该公司表示正在努力调整其Covid-19疫苗以应对奥密克戎变种，并预计如有必要将在100天内准备好新版本。该生物技术公司及其新冠疫苗合作伙伴辉瑞公司几个月前就制定了计划。辉瑞股价收盘下跌3%。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges After Saying Omicron Vaccine Ready Early 2022<blockquote>Moderna表示奥密克戎疫苗将于2022年初准备就绪后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-11-30 09:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.</p><p><blockquote>（彭博社）——Moderna Inc.公布了一年来最好的两天涨幅，此前该公司表示，如果需要，一种对抗冠状病毒奥密克戎株的新疫苗可能会在2022年初准备就绪。</blockquote></p><p> The stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&amp;P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.</p><p><blockquote>该股在周五全球风险资产抛售期间飙升21%后，上涨12%，至9月30日以来的最高水平，重新夺回了今年迄今为止标普500表现最佳的地位。首席医疗官保罗·伯顿(Paul Burton)周末表示，该公司在上周四感恩节动员了数百名员工，开始治疗奥密克戎病毒。</blockquote></p><p> Moderna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.</p><p><blockquote>Piper Sandler分析师Edward A.Tenthoff对该股给予跑赢大盘评级，他表示，Moderna的mRNA技术非常适合使疫苗适应新变种。</blockquote></p><p> “Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”</p><p><blockquote>Tenthoff在给客户的一份报告中写道：“Moderna在开发新型Covid-19疫苗方面处于更有利的地位，现在有能力每月生产数亿剂疫苗。”“新型冠状病毒不会消失，并将提供未来多年的收入。”</blockquote></p><p> Jefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee也对Moderna投资者表示乐观，他表示最新的利差应该会鼓励人们尽早获得提振，而该生物技术公司则专注于2022年的新版本。他说，Moderna“可以在60-90天内将新的候选药物推进临床试验”。</blockquote></p><p> BioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.</p><p><blockquote>BioNTech SE在美国交易中收盘上涨4.2%，此前该公司表示正在努力调整其Covid-19疫苗以应对奥密克戎变种，并预计如有必要将在100天内准备好新版本。该生物技术公司及其新冠疫苗合作伙伴辉瑞公司几个月前就制定了计划。辉瑞股价收盘下跌3%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/moderna-surges-saying-omicron-vaccine-120220663.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199171840","content_text":"(Bloomberg) -- Moderna Inc. posted its best two-day rally in a year after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required.\nThe stock jumped 12% to the highest level since Sept. 30 after surging 21% during Friday’s global risk-asset selloff, to reclaim its place as top performer on the S&P 500 year-to-date. The company mobilized hundreds of workers on Thanksgiving Day last Thursday in order to start work on omicron, Chief Medical Officer Paul Burton said over the weekend.\nModerna’s mRNA technology is ideally suited to adapting vaccines to new variants, according to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the stock.\n“Moderna is in a better position to develop novel Covid-19 vaccines, and now has capacity to manufacture several hundred million vaccine doses every month,” Tenthoff wrote in a note to clients. “SARS-CoV-2 is not going away and will provide years of future revenues.”\nJefferies analyst Michael Yee also struck an optimistic tone for Moderna investors, saying the latest spread should encourage people to get boosted sooner rather than later, while the biotech focuses on a new version for 2022. Moderna “can advance new candidates to clinical trials within 60-90 days,” he said.\nBioNTech SE closed 4.2% higher in U.S. trading after saying it is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary. The biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago. Pfizer shares closed 3% lower.","news_type":1,"symbols_score_info":{"MRNA":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6778685,"gmtCreate":1638236607390,"gmtModify":1638236607419,"authorId":3585186641412013,"author":{"id":3585186641412013,"idStr":"3585186641412013","authorId":3585186641412013,"name":"7cdb98ae","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609390026,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":41,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}